Wuhan HealthGuard (300357.SZ) clinical trial summary report of Artemisia pollen allergen sublingual drops after market launch.

Zhtng Cijng APP news, Wu Corp (300357.SZ) announced that recently, the company's product "Artemisia pollen allergen sublingual drops" (hereinafter referred to as "the product") completed the "Long-term efficacy and safety evaluation of Artemisia pollen allergen sublingual drops in adult patients with allergic rhinitis - multicenter, open-label clinical trial", and formed a summary report of the clinical trial.